Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 589-596

  Murphy, James D ^a   Spalding, Aaron C ^a   Somnay, Yash R ^a   Markwart, Sonja ^a   Ray, Michael E ^a   Hamstra, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; ENDOTHELIUM CELL; FIBROSARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIOSENSITIZATION; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENDOTHELIAL CELLS; ENDOTHELIUM; HUMANS; MICE; MICE, NUDE; MICROCIRCULATION; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; PROTEIN KINASES; RADIATION-SENSITIZING AGENTS; SARCOMA; SIROLIMUS;

EID: 59449111147     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1019     Document Type: Article

References (54)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7.
2. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62.
3. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007;13: 748-53.
4. Li SY, Rong M, Grieu F, lacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer ResTreat 2006;96:91 -5.
5. Samuels Y.Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
6. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21:99-102.
7. Kawaguchi K, Oda Y, SaitoT, et al. Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas. Hum Pathol 2005;36:357-63.
8. Kawaguchi K, Oda Y, SaitoT, et al. DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 2006;19:106-14.
9. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275: 1943-7.
10. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15: 356-62.
11. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420-4.
12. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997;277: 99-101.
13. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA1998;95:1432-7.
14. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998;273:14424-9.
15. Clackson T, Metcalf CA III, Rozamus LW, et al. Regression of tumor xenografts in mice after oral administration of AP23573, a novel mTOR inhibitor that induces tumor starvation. Proc Am Asoc Canc Res 2002;43:34.
16. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984;37:1231 -7.
17. Gibbons JJ, Discafani C, Peterson R, Hernandez R, Skotnicki J, Fruman D. The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenograft in vivo. Proc Am Assoc Cane Res; 1999;40:31.
18. O'Reilly T, Vaxelaire J, Muller MF, Hattenberger M, Lane HA. In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 2002;43:71.
19. SeufferleinT, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 1996;56:3895-7.
20. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mT0R/Hif-1alpha/VEGF signaling. Neoplasia 2006;8:394-401.
21. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
22. Atkins MB, Hidalgo M, Stadler W, et al. A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 21: 2002 (abstr 36).
23. Chan S, Scheulen ME, Johnston S, et al. Phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer (MBC) failing prior anthracycline and/or taxane regimens. Proc Am Soc Clin Oncol 22: 2003 (abstr 774).
24. Chawla SR, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial. 2007 ASCO Annual Meeting; 2007; 2007.
25. Albert JM, Kim KW, Cao C, Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006;5: 1183-9.
26. Contessa JN, Hampton J, Lammering G, et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002;21:4032-41.
27. Cao C, Subhawong T Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006;66: 10040-7.
28. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002;62: 7291 -7.
29. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006;10: 159-70.
30. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005;24:5414-22.
31. Lawrence W, Jr., Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 1987;205:349-59.
32. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
33. Potter DA, Kinsella T, Glatstein E, et al. High-grade soft tissue sarcomas of the extremities. Cancer 1986; 58:190-205.
34. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203.
35. Feng M, Murphy JD, Griffith KA, et al. Long-term outcomes after radiation therapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys 2007;69:103-10.
36. Catton CN, O'Sullivan B, Kotwall C, Cummings B, Hao Y, Fornasier V. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys 1994;29:1005-10.
37. Kilkenny JW III, Bland Kl, Copeland EM III. Retroperitoneal sarcoma: the University of Florida experience. J Am Coll Surg 1996;182:329-39.
38. Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: a useful concept for intercompari-son of human cell survival curves. Radiat Res 1984; 99:73-84.
39. Nor JE, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999;154:375-84.
40. Webb JL. Effect of more than one inhibitor. In Enzyme metabolic inhibitors. New York: Academic press; 1961. p. 66 and 488.
41. Murphy JD, Lucas DR, Somnay YR, Hamstra DA, Ray ME. Gemcitabine-Mediated Radiosensitization of Human Soft Tissue Sarcoma. Transl Oncol 2008;1: 50-6.
42. Petricoin EF III, Espina V, Araujo RP, et al. Phospho-protein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007;67:3431 -40.
43. Bailey HH, Mahoney MR, Ettinger DS, et al. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer 2006;107:2462-7.
44. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6: 729-34.
45. Weppler SA, Krause M, Zyromska A, Lambin P, Baumann M, Wouters BG. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 2007;82:96-104.
46. Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 2005;8: 89-91.
47. Brattstrom C, Sawe J, Jansson B, et al. Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther Drug Monit 2000;22:537-44.
48. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66: 5549-54.
49. Luker KE, Smith MC, Luker GD, Gammon ST, Piwnica-Worms H, Piwnica-Worms D. Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc Natl Acad Sci U S A 2004; 101:12288-93.
50. Kim KW, Mutter RW, Cao C, et al. Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem 2006;281:36883-90.
51. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007;25:4033-42.
52. Moffat BA, Chen M, Kariaapper MS, et al. Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res 2006; 12:1525-32.
53. Lehle K, Birnbaum DE, Preuner JG. Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place. Transplant Proc 2005;37:159- 61.
54. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002;16:771 -80.